The Non-alcoholic Steatohepatitis Therapeutic & Diagnostic Market is expected to register a CAGR of 27.6% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Therapeutic Type (Anti-fibrotic Agents, Anti-inflammatory Agents, Lipid-Lowering Agents, Insulin Sensitizers). The market is further segmented based on by Diagnostic Type (Imaging Systems , Non-invasive Biomarkers, Liver Biopsy). The report is segmented based on End-User (Hospitals, Diagnostic Laboratories, Clinics, Research Institutions). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Non-alcoholic Steatohepatitis Therapeutic & Diagnostic Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Non-alcoholic Steatohepatitis Therapeutic & Diagnostic Market Segmentation
Therapeutic Type- Anti-fibrotic Agents
- Anti-inflammatory Agents
- Lipid-Lowering Agents
- Insulin Sensitizers
- Imaging Systems
- Non-invasive Biomarkers
- Liver Biopsy
- Hospitals
- Diagnostic Laboratories
- Clinics
- Research Institutions
Strategic Insights
Non-alcoholic Steatohepatitis Therapeutic & Diagnostic Market Growth Drivers- Rising Prevalence of NASH: Non-alcoholic steatohepatitis (NASH) is becoming increasingly prevalent due to rising obesity and diabetes rates worldwide. As NASH often progresses to cirrhosis and liver failure, the demand for effective therapeutic and diagnostic solutions is growing, prompting investment in research and drug development to address the increasing burden of liver diseases.
- Increased Awareness and Diagnosis: Growing awareness of NASH among healthcare professionals and the public has resulted in more accurate diagnoses. Earlier detection through improved diagnostic techniques, such as non-invasive biomarkers and imaging tools, is driving the demand for innovative diagnostic solutions, thus expanding the NASH therapeutic and diagnostic market.
- Advancements in Drug Development:Continuous advancements in pharmaceutical research are driving the development of effective treatments for NASH. The development of novel therapies targeting specific molecular pathways involved in liver inflammation and fibrosis is creating a promising market for NASH treatments, attracting investment from biotech and pharmaceutical companies.
- Shift Toward Non-Invasive Diagnostics: There is a growing trend toward non-invasive diagnostic technologies for NASH, including biomarkers and advanced imaging techniques like elastography and MRI. These methods are gaining traction as they provide accurate diagnoses while reducing the need for liver biopsies, offering a less invasive and more cost-effective alternative.
- Personalized Medicine: Personalized or precision medicine is a major trend in the NASH market. Targeted therapies tailored to the genetic and molecular characteristics of individual patients are gaining importance. This approach aims to improve treatment efficacy and minimize side effects, particularly for NASH patients with varying stages of liver damage and fibrosis.
- Collaboration Between Pharma Companies and Research Institutions: Partnerships between pharmaceutical companies and academic research institutions are increasing in the NASH space. These collaborations aim to accelerate the development of NASH therapies and diagnostic tools, leveraging the expertise of both sides to tackle the complex pathophysiology of the disease and improve patient outcomes.
- Emerging Markets: The growing burden of metabolic diseases like obesity and diabetes in emerging markets presents significant opportunities for NASH therapeutics and diagnostics. As healthcare infrastructure improves and access to medical services increases, countries in Asia-Pacific, Latin America, and the Middle East will drive the demand for NASH-related treatments and diagnostic solutions.
- Development of Novel Therapeutic Options: There is a major opportunity for pharmaceutical companies to develop innovative therapies for NASH. Currently, there are no FDA-approved drugs specifically for NASH, and pipeline therapies targeting inflammation, fibrosis, and lipid metabolism are poised to address this unmet need, opening up a vast market for drug developers.
- Expansion of Non-Invasive Diagnostic Solutions: The growing demand for cost-effective, patient-friendly diagnostic solutions represents an opportunity for the expansion of non-invasive testing methods for NASH. Companies focusing on developing and commercializing non-invasive biomarkers and imaging technologies will benefit from the rising demand for early and accurate diagnosis without invasive procedures.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Non-alcoholic Steatohepatitis Therapeutic & Diagnostic Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Non-alcoholic Steatohepatitis Therapeutic & Diagnostic Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The key drivers include the increasing prevalence of NASH due to rising obesity and diabetes rates, growing awareness about the condition, and advancements in drug development that are addressing the unmet need for effective treatments.
Trends include the shift toward non-invasive diagnostic techniques, the rise of personalized medicine to cater to individual patient needs, and collaborations between pharmaceutical companies and research institutions to accelerate the development of therapies and diagnostics.
Opportunities include the growing demand for NASH solutions in emerging markets, the development of novel therapeutic drugs targeting key disease mechanisms, and the expansion of non-invasive diagnostic solutions that offer cost-effective, patient-friendly alternatives to traditional methods.
Challenges include the lack of FDA-approved drugs for NASH, the complexity of the disease's pathophysiology, and the need for more accurate, non-invasive biomarkers and diagnostic tools to detect NASH at early stages.
The rising obesity epidemic significantly contributes to the growing incidence of NASH, thus driving demand for therapeutic and diagnostic solutions to manage and treat liver diseases associated with obesity and metabolic syndrome.
The Asia-Pacific and Latin American regions are expected to witness high growth due to increasing obesity rates, greater healthcare access, and expanding healthcare infrastructure that drive the demand for NASH diagnostics and treatments.
- Intercept Pharmaceuticals, Inc.
- Genfit SA
- Gilead Sciences, Inc.
- Bristol-Myers Squibb
- Pfizer Inc.
- Novo Nordisk A/S
- Medtronic PLC
- Echosens
- HepaDirect
- Terns Pharmaceuticals, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For